PMID- 24206166
OWN - NLM
STAT- MEDLINE
DCOM- 20141212
LR  - 20240502
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 171
IP  - 10
DP  - 2014 May
TI  - The TRPA1 channel in migraine mechanism and treatment.
PG  - 2552-67
LID - 10.1111/bph.12512 [doi]
AB  - Migraine remains an elusive and poorly understood disease. The uncertainty is 
      reflected by the currently unsatisfactory acute and prophylactic treatments for 
      this disease. Genetic and pharmacological information points to the involvement 
      of some transient receptor potential (TRP) channels in pain mechanisms. In 
      particular, the TRP vanilloid 1 (TRPV1) and TRP ankyrin 1 (TRPA1) channels seem 
      to play a major role in different models of pain diseases. Recent findings have 
      underscored the possibility that TRP channels expressed in the nerve terminals of 
      peptidergic nociceptors contribute to the migraine mechanism. Among this channel 
      subset, TRPA1, a sensor of oxidative, nitrative and electrophilic stress, is 
      activated by an unprecedented series of irritant and pain-provoking exogenous and 
      endogenous agents, which release the pro-migraine peptide, calcitonin 
      gene-related peptide, through this neuronal pathway. Some of the recently 
      identified TRPA1 activators have long been known as migraine triggers. 
      Furthermore, specific analgesic and antimigraine medicines have been shown to 
      inhibit or desensitize TRPA1 channels. Thus, TRPA1 is emerging as a major 
      contributing pathway in migraine and as a novel target for the development of 
      drugs for pain and migraine treatment.
CI  - (c) 2013 The British Pharmacological Society.
FAU - Benemei, S
AU  - Benemei S
AD  - Clinical Pharmacology Unit, Department of Health Sciences, University of 
      Florence, Florence, Italy; Headache Centre, Department of Health Sciences, 
      University of Florence, Florence, Italy.
FAU - Fusi, C
AU  - Fusi C
FAU - Trevisan, Gabriela
AU  - Trevisan G
FAU - Geppetti, Pierangelo
AU  - Geppetti P
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Analgesics)
RN  - 0 (Calcium Channels)
RN  - 0 (Ligands)
RN  - 0 (Membrane Transport Modulators)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Receptors, Calcitonin Gene-Related Peptide)
RN  - 0 (TRPA1 Cation Channel)
RN  - 0 (TRPA1 protein, human)
RN  - 0 (Transient Receptor Potential Channels)
RN  - JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
SB  - IM
MH  - Analgesics/*therapeutic use
MH  - Animals
MH  - Calcitonin Gene-Related Peptide/metabolism
MH  - Calcium Channels/metabolism
MH  - Drug Design
MH  - Humans
MH  - Ligands
MH  - Membrane Transport Modulators/*therapeutic use
MH  - Migraine Disorders/*drug therapy/metabolism/physiopathology/psychology
MH  - Molecular Targeted Therapy
MH  - Nerve Tissue Proteins/*antagonists & inhibitors/metabolism
MH  - Pain Perception/drug effects
MH  - Pain Threshold/drug effects
MH  - Receptors, Calcitonin Gene-Related Peptide/metabolism
MH  - TRPA1 Cation Channel
MH  - Transient Receptor Potential Channels/*antagonists & inhibitors/metabolism
PMC - PMC4008999
OTO - NOTNLM
OT  - calcitonin gene-related peptide (CGRP)
OT  - headache
OT  - migraine
OT  - neurogenic inflammation
OT  - neuropathic pain
OT  - oxidative stress
OT  - sensitization
OT  - thermoTRP
OT  - transient receptor potential ankyrin 1 (TRPA1)
EDAT- 2013/11/12 06:00
MHDA- 2014/12/17 06:00
PMCR- 2015/05/01
CRDT- 2013/11/12 06:00
PHST- 2013/09/16 00:00 [received]
PHST- 2013/10/31 00:00 [revised]
PHST- 2013/11/04 00:00 [accepted]
PHST- 2013/11/12 06:00 [entrez]
PHST- 2013/11/12 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
AID - 10.1111/bph.12512 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2014 May;171(10):2552-67. doi: 10.1111/bph.12512.